Oxycodone Use During the Postoperative Period After Hysterectomy for Benign Indications
- PMID: 34264895
- DOI: 10.1097/SPV.0000000000001084
Oxycodone Use During the Postoperative Period After Hysterectomy for Benign Indications
Abstract
Objectives: The objective of this study was to estimate the amount of oxycodone tablets required for pain control in the 2-week postoperative period after laparoscopic hysterectomy (LH) and vaginal hysterectomy (VH) for benign disease.
Methods: We conducted a prospective cohort study of English-speaking women 18 years or older undergoing hysterectomy for benign indications. Participants completed a pain survey at baseline and daily for 2 weeks postoperatively. In addition, they recorded the number of oxycodone tablets and other pain medications taken daily for 2 weeks. The primary outcome was the median number of oxycodone tablets (5 mg) consumed after LH or VH during 2 weeks postoperative.
Results: Eighty-one women underwent VH and 82 underwent LH. Women who underwent VH were older (mean ± SD, 64.2 ± 10.3 years vs 47.5 ± 7.7 years), more parous (2 [interquartile range (IQR), 2-3] vs 2 [IQR, 1-2]), and less likely to be sexually active (51.9% vs 79.3%, P < 0.02). Women in the VH group also had significantly lower baseline pain levels (0 [IQR, 0-1] vs 1 [IQR, 0-4], P < 0.001). All VH participants had surgery for prolapse, whereas only 12.2% in the LH group had surgery for this indication (P < 0.001). Most in the LH group had surgery for fibroids (61%) or abnormal uterine bleeding (15.9%). Women in the VH group consumed significantly less oxycodone tablets postoperatively (median, 4.5 [IQR, 1-9] vs 7 [IQR, 2-18]; P = 0.047) and took oxycodone for less days after discharge (median, 1 [IQR, 0-3] vs 3 [IQR, 1-6]; P < 0.001).
Conclusions: Women consume less oxycodone after minimally invasive hysterectomy than previously thought. Those who undergo VH may consume less oxycodone than those who undergo LH.
Copyright © 2021 American Urogynecologic Society. All rights reserved.
Conflict of interest statement
J.M.M. is an advisor for Attn: Grace. S.L.C. is a Myovant advisory board member. The remainder of the authors reports no conflicts of interest.
References
-
- FDA News Release. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death. March 2016. Available at: https://www.fda.gov/news-events/press-announcements/fda-announces-enhanc.... Accessed February 14, 2020.
-
- Thompson JC, Komesu YM, Qeadan F, et al. Trends in patient procurement of postoperative opioids and route of hysterectomy in the United States from 2004 through 2014. Am J Obstet Gynecol 2018;219:484.e1–484.e11. doi:10.1016/j.ajog.2018.07.003. - DOI
-
- Garry R, Fountain J, Mason S, et al. The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. BMJ 2004;328:129. doi:10.1136/bmj.37984.623889.F6. - DOI
-
- Schütz K, Possover M, Merker A, et al. Prospective randomized comparison of laparoscopic-assisted vaginal hysterectomy (LAVH) with abdominal hysterectomy (AH) for the treatment of the uterus weighing >200 g. Surg Endosc 2002;16(1):121–125. doi:10.1007/s00464-001-0049-8. - DOI
-
- Brunes M, Habel H, Altman D, et al. Risk-factors for continuous long-term use of prescription opioid drugs 3 years after hysterectomy: a nationwide cohort study. Acta Obstet Gynecol Scand 2020;99:1057–1063. doi: 10.1111/aogs.13826. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources